Wednesday 27 February 2013

Drug Patent Expirations for the week of February 24, 2013


Drug Patent Expirations for the week of February 24, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
PREZISTAJanssen Prodsdarunavir ethanolate6,335,460*PEDFeb 25, 2013
DATSCANGe Hlthcare Incioflupane i-1235,310,912Feb 25, 2013
THALOMIDCelgenethalidomide7,723,361Mar 1, 2013
THALOMIDCelgenethalidomide6,235,756Mar 1, 2013
THALOMIDCelgenethalidomide8,143,283Mar 1, 2013
LUNESTASunovion Pharms Inceszopiclone6,864,257*PEDMar 2, 2013
ZOMETANovartiszoledronic acid4,939,130*PEDMar 2, 2013
RECLASTNovartiszoledronic acid4,939,130*PEDMar 2, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Andhra Pradesh :PGECET 2013 Notification

Thursday 21 February 2013

Drug Patent Expirations for the week of February 17, 2013


Drug Patent Expirations for the week of February 17, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
ARRANONSmithkline Beechamnelarabine5,821,236Feb 20, 2013
ARRANONSmithkline Beechamnelarabine5,492,897Feb 20, 2013
ARRANONSmithkline Beechamnelarabine5,747,472Feb 20, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,753,006Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,096,331Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel5,439,686Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,749,868Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,537,579Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,506,405Feb 22, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Drug Patent Expirations for the week of February 17, 2013


Drug Patent Expirations for the week of February 17, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
ARRANONSmithkline Beechamnelarabine5,821,236Feb 20, 2013
ARRANONSmithkline Beechamnelarabine5,492,897Feb 20, 2013
ARRANONSmithkline Beechamnelarabine5,747,472Feb 20, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,753,006Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,096,331Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel5,439,686Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,749,868Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,537,579Feb 22, 2013
ABRAXANEAbraxis Biosciencepaclitaxel6,506,405Feb 22, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Thursday 14 February 2013

Drug Patent Expirations for the week of February 10, 2013


Drug Patent Expirations for the week of February 10, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
COLESTIDPharmacia And Upjohncolestipol hydrochloride5,490,987Feb 13, 2013
ZOLOFTPfizersertraline hydrochloride5,248,699*PEDFeb 13, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Tuesday 5 February 2013

Drug Patent Expirations for the week of February 3, 2013


Drug Patent Expirations for the week of February 3, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
IMODIUM MULTI-SYMPTOM RELIEFMcneilloperamide hydrochloride; simethicone5,489,436Feb 6, 2013
IMODIUM A-D EZ CHEWSMcneilloperamide hydrochloride5,489,436Feb 6, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Friday 1 February 2013

Drug Patent Expirations for the week of January 20 & 27, 2013


Drug Patent Expirations for the week of January 20, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
MERIDIAAbbottsibutramine hydrochloride5,436,272*PEDJan 25, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Drug Patent Expirations for the week of January 27, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
STARLIXNovartisnateglinide5,488,150Jan 30, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.